Rocakinogene sifuplasmid

DB16316Investigational

Rocakinogene sifuplasmid is under investigation in clinical trial NCT03491683 (INO-5401 and INO-9012 Delivered by Electroporation (EP) in Combination With Cemiplimab (REGN2810) in Newly-diagnosed Glioblastoma (GBM)).

Mechanism: Pharmacologically active on Interleukin-12 receptor subunit beta-1 and Interleukin-12 receptor subunit beta-2
Curator reviewed
Code names: INO-9012

Resolves to

Compound

UNII91JHE0ANN8CAS2253753-17-0

Targets

P42701IL12RB1Q99665IL12RB2

What you can answer from here — as of July 08, 2026

2Protein targetsEach mapped to UniProt, with action and pharmacological action

Listed above

14Clinical trialsPhase, status and sponsor resolved per trial

6+ReferencesStructured and connected to the statements they support

Which drugs share a target with Rocakinogene sifuplasmid, and which of those have an active Phase 3 trial?

Answer this in Biopharma OS Sign in to your account

Create a free account or log in to explore the full data card.

Create Account